Skip to main content

Advertisement

Table 1 Baseline characteristics of treated patients.

From: Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

ID Number Gender Age (years) KPS (%) HLA-A2 LDH Stage IV Sites of Metastasis Prior Cytokine Therapy Prior Chemotherapy
0001–1103 M 49 80 + 169 M1b Abdominal wall, thorax IL2 Yes
0002–2101 M 30 90 + 130 M1b Lung IL2 No
0002–2102 F 39 80 + 429 M1c Skin, lymph nodes, liver IFNα2b Yes
0003–3101 M 44 90 - 575 M1c Skin, lymph nodes, lung IL2 and IFNα2b Yes
0003–3102 M 67 80 + 1388 M1c Lymph nodes, skin, lung, liver IL2 and IFNα2b Yes
0004–4101 M 40 100 + 132 M1a Skin IFNα2b No
0004–4102 M 36 90 + 333 M1c Lymph nodes, spleen, liver IFNα2b Yes
0004–4103 F 54 90 - 94 M1c Skin, liver IFNα2b No
0004–4104 M 76 90 - 282 M1c Skin, lung IFNα2b No
  1. ID = identification. KPS = Karnofsky performance status. LDH = lactate dehydrogenase (on Day 1 of Cycle 1). M = male. F = female. IFN = interferon. IL2 = interleukin-2.